← Back to list
08.01.36i, Therapies for Spinal Muscular Atrophy
Effective date
Sep 14, 2026
Identified
Sep 15, 2026
Summary
Independence Blue Cross expanded coverage for Spinal Muscular Atrophy therapies effective 09/14/2026 to include Itvisma (onasemnogene abeparvovec-brve) and a new higher-dose regimen of Spinraza (nusinersen) at 50 mg loading doses followed by 28 mg maintenance every 4 months. The policy now offers two dosing pathways—lower dose (12 mg maintenance) and higher dose (28 mg maintenance)—both requiring documented motor function improvement or stabilization for continuation therapy.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 6 steps
01Billing team must update billing system and prior authorization logic to recognize two distinct Spinraza dosing regimens—lower dose (12 mg loading, 12 mg maintenance q4m) and higher dose (50 mg loading, 28 mg maintenance q4m)—ensuring claims are not denied for the newly covered higher-dose pathway.
02Update prior authorization templates and claim submission guidelines to specify which regimen is being requested and ensure supporting genetic testing documentation is attached.
03Providers (neurologists and physiatrists with neuromuscular subspecialty certification) must document baseline motor function assessment using HINE, CHOP-INTEND, or HFMSE scores before initiating either regimen.
04Billing and clinical staff must verify that continuation therapy claims include documented evidence of motor function improvement, stability, or slower decline on the same standardized assessment scale used at baseline.
05Add Itvisma (HCPCS J3405) to covered SMA therapy protocols and ensure claims processing recognizes it as medically necessary.
06Update encounter forms and EHR templates to capture dosing regimen selection and motor function assessment scores.
If missed: Failure to update system logic and documentation practices will result in claim denials for the new higher-dose Spinraza regimen and Itvisma claims.
Codes mentioned
J2326J3399J3405
Original notice
08.01.36i, Therapies for Spinal Muscular Atrophy
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →08.01.36h, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)MediumEffective Jul 1, 2026 · Pharmacy08.01.36e, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)HighEffective Jul 1, 2020 · Pharmacy08.01.36f, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)MediumEffective Mar 23, 2026 · Pharmacy08.01.36g, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)MediumEffective Apr 1, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list